Skip to content
Home
Clinical trials
Glossary
Contact us
Sitemap
1033ID/0029
For 1033ID/0029, several sets of results are provided as follows:
Approval date 6 February 2002
: this is the one-year protocol-defined analysis and the data cut-off date 14th June 2001.
Approval date 25 March 2003
: this is the two-year, protocol-defined analysis and the data cut-off date 30th May 2002.
Approval date 31 January 2006
: this is the five-year, protocol-defined analysis and the data cut-off date 1st March 2005.
Approval date 3 May 2008:
this is the seven-year, protocol-defined analysis and the data cut-off date 30 April 2007.
.
AstraZeneca websites
Search
Advanced search
Corporate Responsibility
Bioethics Policy
Code of Conduct
Quick links - Products
Accolate™ (zafirlukast)
Arimidex™ (anastrozole)
Atacand™ (candesartan cilexetil)
Casodex™ (bicalutamide)
Crestor™ (rosuvastatin)
Diprivan™ (propofol)
Entocort™ (budesonide)
Exanta™ (ximelagatran)
Faslodex™ (fulvestrant)
Iressa™ (gefitinib)
Losec™ (omeprazole)
Merrem™ (meropenem)
Naropin™ (ropivacaine)
Nexium™(esomeprazole)
Oxis™ (formoterol)
Plendil™ (felodipine)
Pulmicort™ (budesonide)
Rhinocort™(budesonide)
Seloken ZOK/Toprol-XL™ (metoprolol CR/XL)
Seroquel™ (quetiapine)
Symbicort™ (budesonide/formoterol)
Tomudex™ (raltitrexed)
Zoladex™ (goserelin acetate)
Zomig™ (zolmitriptan)
Products in Development
Non-Drug Trials
Page tools
Bookmark this site
Bookmark this page
Printer friendly
Print this chapter
Legal notice
Privacy policy
© AstraZeneca 2005